Insider Selling: Scott Biller Unloaded 3,000 Shares of Agios Pharmaceuticals, Inc. (AGIO); Bok Financial (BOKF) Sentiment Is 1

BOK Financial Corporation, a financial holding company, operates BOKF, NA that provides various financial services and products in Oklahoma, Texas, New Mexico, Northwest Arkansas, Colorado, Arizona, and Kansas/Missouri. The company has market cap of $6.13 billion. It operates through three divisions: Commercial Banking, Consumer Banking, and Wealth Management. It has a 18.34 P/E ratio. The Commercial Banking segment offers lending, treasury and cash management services, and customer risk management products for small businesses, middle market, and larger commercial customers.

An insider of the company Agios Pharmaceuticals Inc, Scott Biller also its Chief Scientific Officer, disclosed his trading activities with the SEC on 07/02/2018. As revealed in the document, Scott had unloaded 3,000 shares of the Pinksheet-listed company. The total sale was worth $228,128 US Dollars. At the time of the transaction the price of a share was $76.0. In the last 30 days, he also sold 3,000 shares with a total value $195,000 USD. And, It’s sure Scott’s sell isn’t going to stay hidden as he right now is holding 53,059 shares – ( 0.10% of Agios Pharmaceuticals Inc’s Market Cap ).

Ratings analysis reveals 20% of BOK Financial’s analysts are positive. Out of 5 Wall Street analysts rating BOK Financial, 1 give it “Buy”, 0 “Sell” rating, while 4 recommend “Hold”. The lowest target is $68.0 while the high is $94.0. The stock’s average target of $78.67 is -16.04% below today’s ($93.7) share price. BOKF was included in 5 notes of analysts from October 7, 2016. On Friday, October 7 the stock rating was maintained by Wedbush with “Neutral”. On Thursday, October 27 the stock rating was upgraded by Macquarie Research to “Neutral”. The rating was upgraded by Hovde Group on Monday, December 12 to “Outperform”. RBC Capital Markets maintained the shares of BOKF in report on Thursday, October 27 with “Sector Perform” rating. The company was upgraded on Monday, January 9 by Wells Fargo.

George Kaiser Family Foundation holds 81.46% of its portfolio in BOK Financial Corporation for 2.00 million shares. Reinhart Partners Inc. owns 256,891 shares or 2.42% of their US portfolio. Moreover, Skba Capital Management Llc has 2.18% invested in the company for 170,410 shares. The California-based Aristotle Capital Management Llc has invested 1.43% in the stock. Avenir Corp, a -based fund reported 148,670 shares.

The stock increased 0.16% or $0.15 during the last trading session, reaching $93.7. About 82,377 shares traded. BOK Financial Corporation (BOKF) has risen 36.84% since February 7, 2017 and is uptrending. It has outperformed by 20.14% the S&P500.

Analysts await Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) to report earnings on February, 15. They expect $-1.65 earnings per share, down 23.13% or $0.31 from last year’s $-1.34 per share. After $-1.59 actual earnings per share reported by Agios Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 3.77% negative EPS growth.

Among 16 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Agios Pharmaceuticals has $132 highest and $47 lowest target. $75.64’s average target is -2.31% below currents $77.43 stock price. Agios Pharmaceuticals had 41 analyst reports since July 23, 2015 according to SRatingsIntel. On Monday, September 18 the stock rating was maintained by J.P. Morgan with “Buy”. On Thursday, June 1 the stock rating was maintained by Oppenheimer with “Buy”. Oppenheimer maintained it with “Buy” rating and $7500 target in Monday, June 26 report. TH Capital maintained the stock with “Neutral” rating in Monday, November 9 report. Oppenheimer maintained Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Sunday, June 11 with “Buy” rating. Roth Capital maintained Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) rating on Monday, November 9. Roth Capital has “Neutral” rating and $75 target. On Wednesday, August 5 the stock rating was maintained by Roth Capital with “Hold”. The rating was initiated by Northland Capital with “Outperform” on Thursday, July 23. The rating was maintained by Suntrust Robinson on Wednesday, May 18 with “Buy”. JP Morgan upgraded Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Monday, June 13 to “Overweight” rating.

Investors sentiment decreased to 1.21 in Q3 2017. Its down 0.83, from 2.04 in 2017Q2. It worsened, as 22 investors sold Agios Pharmaceuticals, Inc. shares while 44 reduced holdings. 29 funds opened positions while 51 raised stakes. 44.69 million shares or 0.07% less from 44.72 million shares in 2017Q2 were reported. Zurcher Kantonalbank (Zurich Cantonalbank) reported 1,838 shares stake. Deerfield Mngmt Company reported 208,000 shares stake. Alkeon Capital Mgmt Ltd Llc owns 456,761 shares. Oppenheimer And Incorporated holds 21,445 shares. Ny State Common Retirement Fund holds 94,000 shares. Axa holds 0.05% or 161,743 shares in its portfolio. Moreover, Parametric Port Associates Ltd Liability has 0% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 21,565 shares. Sarl holds 0.73% or 130,800 shares. Prelude Cap Management Ltd Co reported 0.03% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Sg Americas Limited Liability accumulated 7,625 shares. Moreover, Credit Suisse Ag has 0.01% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Cap Guardian Com holds 729,714 shares or 0.85% of its portfolio. Eventide Asset Management Limited Liability Corporation reported 0.81% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Royal Bancorporation Of Canada reported 91,155 shares stake. Ahl Ptnrs Llp accumulated 6,971 shares or 0.01% of the stock.

The stock increased 0.79% or $0.61 during the last trading session, reaching $77.43. About 372,612 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 8.52% since February 7, 2017 and is uptrending. It has underperformed by 8.18% the S&P500.